Search the Newsreel

ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00

HC Wainwright has increased its price target for ArriVent BioPharma (NASDAQ:AVBP) to $47.00 from $44.00, maintaining a "buy" rating and implying a 59% upside. This comes amidst a generally positive analyst sentiment, with eight analysts rating the stock a "Buy," one a "Hold," and …

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

Monaco Asset Management SAM has acquired a new stake worth $8.48 million in Rocket Pharmaceuticals (NASDAQ: RCKT), making it the firm's 11th largest holding and representing 2.27% of the biotechnology company's shares. Despite institutional investors owning 98.39% of the stock and the company beating …

Radiopharm schedules FDA meeting for brain imaging agent RAD101 By Investing.com

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the Phase 3 trial design for its brain imaging agent, RAD101. RAD101, which has FDA Fast Track Designation, is developed to diagnose recurrent brain metastases and showed …

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics is scheduled to meet with the U.S. FDA on October 1st, 2026, for an End-of-Phase 2 meeting to discuss the pivotal Phase 3 trial design for RAD101. This imaging agent, which targets fatty acid synthase (FASN), is being developed for the diagnosis …

A PET scan matched MRI in 93% of lesions—what comes next?

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …

NRX Pharmaceuticals reports $18.0M net loss for first half 2026, $26.7M cash on hand

NRX Pharmaceuticals reported a net loss of $18.0 million for the first half of 2026, with an operating loss widening to $11.3 million. The company holds $26.7 million in cash and expects current resources, revenue growth, and an at-the-market facility to fund operations for …

Neuberger Berman Next Generation Connectivity Fund Inc.'s Dividend Analysis

Neuberger Berman Next Generation Connectivity Fund Inc. (NBXG) recently announced a $0.12 per share cash dividend with an ex-dividend date of 2026-08-17. The article analyzes NBXG's dividend history, yield, growth rates, and sustainability, noting an attractive forward dividend yield of 9.07% and a low …

Hyphens Pharma Lifts Margins and Profit as Portfolio Revamp Takes Hold

Kelun-Biotech Announces 2026 Interim Results

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period"). Key information is as follows: Revenue amounted to approximately RMB …

Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRN

Persistent Asset Partners Ltd has made a new investment of $4.57 million in BioMarin Pharmaceutical Inc., acquiring 79,933 shares, which now constitutes 1.4% of its portfolio. BioMarin recently reported strong Q2 earnings, surpassing analyst estimates with $1.20 EPS and $989.71 million in revenue, and …

Monaco Asset Management SAM Invests $10.58 Million in BioMarin Pharmaceutical Inc. $BMRN

Monaco Asset Management SAM has invested $10.58 million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), acquiring 184,937 shares, making it their eighth-largest holding. This investment comes as BioMarin reported strong quarterly earnings, beating analyst estimates with $1.20 EPS and a 20% revenue increase year-over-year. Analysts generally …

UBS raises Acadia Pharmaceuticals stock price target on trial optimism

UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating, due to increased optimism for its drug remlifanserin in Alzheimer’s disease psychosis. The firm raised its probability of success for remlifanserin to 50% and its …

Mizuho raises Amylyx stock price target to $30 on higher pricing

Mizuho has increased its price target for Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) shares to $30 from $24, while maintaining an Outperform rating, due to updated pricing assumptions for its lead asset, avexitide. The firm anticipates positive Phase 3 LUCIDITY study data for avexitide in late …

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter

NRx Pharmaceuticals reported its second-quarter 2026 financial results, highlighting significant progress in advancing its preservative-free ketamine ANDA towards FDA approval and commercialization. The company secured $22.3 million in gross proceeds from a public offering, ensuring over a year of operations, and expanded its clinical …

EyePoint’s DURAVYU misses primary endpoint in wet AMD trial

EyePoint, Inc. announced that its Phase 3 LUGANO trial for DURAVYU in wet AMD treatment failed to meet its primary endpoint, largely due to an asymmetric cohort of patients experiencing vision loss unrelated to wet AMD. Despite this, an ad hoc analysis showed non-inferiority …

Two Squeezed Hyperscalers: Does Meta or Amazon Have The Bigger Cash Flow Problem?

Quick Read AMZN burned -$8.8B in free cash flow last quarter, but META's slim $784M surplus masks deeper structural risk with no cloud revenue to recoup hardware costs. AWS hit a 39% margin with a $496B backlog, giving Amazon a metered cash recovery loop …

Weekly Recap: 191 MW Rockdale supply deal and pivot to AI data centers

Riot Platforms (RIOT) is transitioning its business focus from Bitcoin mining to AI data centers, securing a 20-year, 191 MW deal with Anthropic for its Rockdale facility. This strategic shift comes amid falling miner revenues and rising power costs, with the company reporting strong …

Firm Capital Mortgage Invest Corp FC Earnings Miss Estimates by 8.0%

From Hikma Pharmaceuticals (LSE:HIK) To Spire Healthcare Group (LSE:SPI): What Is Separating Healthcare Stocks Today?

Which part of the Poolbeg Pharma (LSE:POLB) immunotherapy story is driving UK small-cap interest today?

Google, Amazon, and Meta All Just Raised Capex Guidance Again. This Boring Industrial Wins No Matter Whose AI Infrastructure Is Best.

If there was any worry that spending on artificial intelligence (AI) was finally set to slow down, it's just been wiped away. Not only are big tech companies not dialing back their aggressive investments in AI infrastructure, but they're ramping them up. Google parent …

Aarey Drugs Q1 Results: Revenue up 145% YoY, net profit falls 60%

Veradermics, Inc SEC Filing (Aug 17, 2026)

Veradermics, Inc. (NYSE: MANE) had an EFFECT filing accepted by the SEC EDGAR on August 17, 2026, with an effectiveness date of August 14, 2026, at 4:00 P.M. The filing was Form S-1. The company's recent news includes financial results, clinical progress updates, and …

Traws Pharma beats Q2 loss estimates, shares jump 4%

AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA

AIGH Capital Management LLC has acquired a new stake of over 2 million shares in Vanda Pharmaceuticals Inc., valued at approximately $12.5 million, making it their 21st largest position. Analyst sentiment for Vanda Pharmaceuticals is mixed but leans positive, with a "Moderate Buy" consensus …

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA

Monaco Asset Management SAM has acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), purchasing 221,286 shares valued at approximately $1.35 million. This investment makes Vanda Pharmaceuticals 0.1% of Monaco Asset Management SAM's portfolio and represents about 0.37% ownership of the company. The biopharmaceutical …

Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher

Kitex Garments Q1 FY27 Results: Revenue fell to Rs 158 Cr, Net Loss -189%

2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC

Simplicity Wealth LLC recently acquired 2,792 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $1.39 million during the second quarter. Vertex reported quarterly revenue of $3.33 billion, exceeding estimates, though its EPS of $4.73 narrowly missed consensus. The company holds a "Moderate Buy" rating …

Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX

Plato Investment Management Ltd recently acquired 6,083 shares of Vertex Pharmaceuticals (NASDAQ:VRTX) valued at approximately $3 million during the second quarter. Other institutional investors have also increased their holdings, leading to institutions collectively owning 90.96% of the company's stock. Despite some insider selling, analysts …

Trivium Point Advisory LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

Trivium Point Advisory LLC has acquired a new stake in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,199 shares valued at approximately $1.092 million during the second quarter. Other institutional investors have also recently adjusted their holdings in the pharmaceutical company, which reported quarterly earnings that narrowly …

Prostarm Info Systems FY26 Results: Net profit up 14% YoY

West Pharmaceutical Services (WST): Analyst Consensus And 15.83% Potential Upside

West Pharmaceutical Services (WST) is a key healthcare player specializing in injectable drug delivery systems, showing strong market presence and promising growth. The company, with a market capitalization of $24.59 billion and a stock price of $349.42, has a robust forward P/E of 35.07 …

Orchid Pharma Q1 FY27 Results: Revenue grew to Rs 304 Cr, PAT -78%

Focus Partners Advisor Solutions LLC Sells 21,281 Shares of CarMax, Inc. $KMX

Focus Partners Advisor Solutions LLC significantly reduced its stake in CarMax, Inc. (NYSE:KMX) by 50% in the second quarter, selling 21,281 shares and now owning 21,323 shares valued at $1.128 million. Other institutional investors have also adjusted their positions, while CarMax received a "Strong …

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Earlier this month, BioMarin Pharmaceutical reported second-quarter 2026 results showing revenue of US$989.71 million and updated earnings guidance for the second half and full year, including a slight increase in its 2026 revenue outlook to US$3.88 billion–US$3.93 billion. Alongside these results, BioMarin filed a …